Braun H, Weber F
Bayer (Schweiz) AG, Zurich, Switzerland.
J Cardiovasc Pharmacol. 1991;18 Suppl 1:S59-62.
Efficacy and tolerability of antihypertensive monotherapy with the calcium antagonist nitrendipine were investigated in a 6-month open trial in 495 patients with mild to moderate essential hypertension from 101 practicing internists and general practitioners. Previous antihypertensive therapy (57.4%) was stopped for 1 week and therapy then started with nitrendipine, 20 mg once daily. Sixty-one patients discontinued therapy prematurely because of unwanted effects, mostly characteristic with dihydropyridines (headaches, flushing, and ankle edema), and 23 patients because of insufficient efficacy. In 75% of the remaining 411 patients, the goal blood pressure was achieved by nitrendipine monotherapy (10 mg in 17.6%, 20 mg in 73.3%, and 20 mg b.i.d. in 8%) and diastolic blood pressure was between 90 and 95 mm Hg in another 6%. The reduction in blood pressure did not result in changes of heart rate or weight. Nitrendipine was effective in patients of all age groups but patients older than 60 years of age showed a significantly greater fall in systolic pressure than middle-aged or young patients. At the end of the study, 15 patients still reported side effects. Nitrendipine appears to be well suited for first-line therapy of mild to moderate essential hypertension.
在一项为期6个月的开放试验中，101名内科实习医生和全科医生对495例轻至中度原发性高血压患者使用钙拮抗剂尼群地平进行了抗高血压单药治疗的疗效和耐受性研究。先前的抗高血压治疗（57.4%）停药1周，然后开始使用尼群地平治疗，每日一次，每次20毫克。61例患者因不良反应（主要是二氢吡啶类药物的典型症状，如头痛、脸红和踝部水肿）提前停药，23例患者因疗效不佳停药。在其余411例患者中，75%通过尼群地平单药治疗达到了目标血压（17.6%为10毫克，73.3%为20毫克，8%为每日两次20毫克），另有6%的患者舒张压在90至95毫米汞柱之间。血压降低并未导致心率或体重变化。尼群地平对所有年龄组的患者均有效，但60岁以上的患者收缩压下降幅度明显大于中年或年轻患者。研究结束时，仍有15例患者报告有副作用。尼群地平似乎非常适合轻至中度原发性高血压的一线治疗。
